Description
AXL is currently under investigation for its potential use in colorectal cancer (CRC) as a single agent or in combination with other therapies. Its role in clinical practice has not been established yet due to ongoing research and lack of FDA approval.
Mechanism of Action
AXL is an investigational small molecule inhibitor targeting the receptor tyrosine kinase AXL, which plays a role in tumor progression and resistance to therapy.
Side Effects
Fatigue; Nausea; Diarrhea; Hematological toxicity
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT04842812
med_phase_prefix1
Recruiting
Engineered TILs/CAR-TILs to Treat Advanced Solid Tumors
China